Abstract 3565
Background
Pooled analyses from 2 phase III trials of patients (pts) with metastatic breast cancer (mBC) treated with eribulin (E) versus other chemotherapy showed improved overall survival (OS) favoring E. Subsequent subgroup analyses, including pts with visceral metastases (VM), also showed improved OS when treated with E. Current 3rd line mBC chemotherapy options include E, gemcitabine (G) and capecitabine (C), among others. This study evaluated 1-year (yr) OS in a real world setting among mBC pts with VM treated with E, G, or C in a US cancer center network.
Methods
This retrospective study investigated pts with mBC with biopsy proven VM (liver and/or lung), treated with E, G, or C in 3rd line chemotherapy from 1/1/2012 to 11/1/2018. Electronic health records and cancer registry data were used to detect differences in OS (number of mons from start of 3rd line until death). Univariate and multivariate analyses of 1-yr survival between E, G, and C were conducted using Kaplan Meier (KM) and Cox proportional hazard (CPH) models respectively.
Results
Of 1,828 mBC pts, 1,417 had VM, and 443 (27.5% triple negative, 13.7% HER2+ and 51.9% ER+/PR+) received 3rd line therapy with E = 229 (51.7%), G = 134 (30.2%) or C = 80(18.1%). On average, E, G, and C pts did not differ by age, ethnicity, BMI or ECOG score (categorized as good [0-1] and poor [>2]), but E pts had higher mean income compared to G or C. 1-yr KM survival analyses included 370 pts (n = 195 E, 117 G, and 58 C) with at least 1-yr follow up. 150 patients (45% E, 33% G, and 41% C) were alive at the end of 1-yr. Survival curves between E, G, and C differed significantly (Logrank p < 0.05; Wilcoxon p < 0.05). Censored median survival of E pts was 9.75 mons compared to 6.95 for G (p < 0.05) and 7.48 for C pts, respectively. CPH analysis adjusted for age, ethnicity, ECOG score, BMI, and adverse events showed significant survival benefit for E pts compared to G (HR = 0.71, p < 0.05), but no significant differences between E vs C or C vs G pts.
Conclusions
This real-world 1-yr survival analysis of pts with mBC and VM demonstrated significantly better OS for pts receiving E as compared to G, and a trend favoring OS for patients receiving E in comparison to C.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Eisai Inc.
Funding
Eisai Inc.
Disclosure
S.M. Kazmi: Speaker Bureau / Expert testimony: Eisai, Takeda, Lilly, Merck; Advisory / Consultancy: Merck, Takeda. E. Wang: Non-remunerated activity/ies, Eisai employee at the time of research: Eisai. R.S. Hauser: Research grant / Funding (institution): Eisai. P.A. Kaufman: Advisory / Consultancy, Research grant / Funding (institution), research grant support, and consulting fees: Eisai. All other authors have declared no conflicts of interest.
Resources from the same session
3082 - Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): a pooled analisys of TRIBE and TRIBE-2 studies by GONO
Presenter: Emanuela Dell'Aquila
Session: Poster Display session 2
Resources:
Abstract
3618 - Drug holidays and overall survival in patients treated for metastatic colorectal cancer
Presenter: Silvio Ken Garattini
Session: Poster Display session 2
Resources:
Abstract
6111 - Quality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)
Presenter: Michael Geissler
Session: Poster Display session 2
Resources:
Abstract
1042 - A biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastastic colorectal cancer : results of phase I of the PERMAD trial
Presenter: Thomas Seufferlein
Session: Poster Display session 2
Resources:
Abstract
3291 - Microsatellite Instability (MSI) status and prognosis in colorectal cancer: meta-analysis
Presenter: James Toh
Session: Poster Display session 2
Resources:
Abstract
2046 - Choosing the right strategy based on individualized treatment effect predictions: Combination versus sequential chemotherapy in patients with metastatic colorectal cancer.
Presenter: Miriam Koopman
Session: Poster Display session 2
Resources:
Abstract
2589 - Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer
Presenter: Stefan Kasper
Session: Poster Display session 2
Resources:
Abstract
4944 - POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers
Presenter: Maria Elena Elez Fernandez
Session: Poster Display session 2
Resources:
Abstract
2042 - The accuracy of the clinical PCI score in patients with peritoneal carcinomatosis of colorectal cancer
Presenter: Nadine De Boer
Session: Poster Display session 2
Resources:
Abstract
2667 - The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC).
Presenter: Takeshi Kawakami
Session: Poster Display session 2
Resources:
Abstract